Evidence map›Paper›PMID 40936164›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

CDK4/6 Inhibitor Priming Enhances PD-1 Blockade via Sell

Yu Zhang, Bao Sun, Rong Zhou, Zizhen Gong, Yong Han, Wenjie Tao, Chaoji Shi, Wuchang Zhang, Laikui Liu, Zhiyuan Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. CDK4/6 Inhibitor Priming Enhances PD-1 Blockade via SellAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yu ZhangDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Bao SunCollege of Stomatology, Shanghai Jiao Tong University, Shanghai, 200011, China.
Rong ZhouDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Zizhen GongState Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Nanjing Medical University, Nanjing, 210029, China.
Yong HanDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Wenjie TaoDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Chaoji ShiDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Wuchang ZhangLaboratory of Oral Microbiota and Systemic Diseases Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Laikui LiuState Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Nanjing Medical University, Nanjing, 210029, China.
Zhiyuan ZhangDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Jiang LiCollege of Stomatology, Shanghai Jiao Tong University, Shanghai, 200011, China.
Qi ZhuDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.
Weiwen ZhuDepartment of Oral Mucosal Diseases, The Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, 210029, China.
Ziyue GuDepartment of Oral Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.ORCID https://orcid.org/0000-0002-8926-1754

Funding

China Postdoctoral Science Foundation 2023M732282Clinical Research Plan of SHDC SHDC2023CRT009National Key Research and Development Program of China 2022YFC2504200National Natural Science Foundation of China 82002862National Natural Science Foundation of China 82303307National Natural Science Foundation of China 82303788National Natural Science Foundation of China 82303973Shanghai "Rising Stars of Medical Talents" Youth Development Program SHWSRS(2024)_070Young Elite Scientist Sponsorship Program by CAST 2022QNRC001
6 · The paper itself

Abstract

Cell cycle pathway, especially via cyclin D1-CDK4/6 signaling, is enriched in immunotherapy-resistant and immune-excluded tumors. CDK4/6 inhibitor (CDK4/6i) induces antitumor immune phenotypes by targeting both tumor and immune cells, enhancing immune checkpoint blockade (ICB), but optimal combination modalities and the corresponding cellular mechanisms remain unclear. Here, it is shown that activation of tumor cell-intrinsic cyclin D1-CDK4/6 signaling is associated with low tumor-infiltrating lymphocyte populations and immunotherapy resistance in head and neck squamous cell carcinoma (HNSCC). Comparison of sequential versus combinatorial regimens in subcutaneous or orthotopic HNSCC mice revealed that CDK4/6i priming before anti-PD-1 enhances response durability by promoting CD8

Indexed as

CD8-Positive T-LymphocytesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Head and Neck NeoplasmsImmune Checkpoint InhibitorsNeutrophilsProgrammed Cell Death 1 ReceptorSquamous Cell Carcinoma of Head and NeckSTAT5 Transcription FactorAnimalsCell Line, TumorHumansMiceTumor Suppressor ProteinsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorSTAT5A protein, humanSTAT5 Transcription FactorTumor Suppressor ProteinsCD8+TpexCDK4/6i primingHNSCCSell(hi) neutrophilsStat5a

Identifiers

PMID40936164
PMCPMC12667468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.